Research Use Only (RUO). This article is for education and shares what published science says about a research compound. It is not medical advice, and nothing here is a suggestion to use any peptide on people or animals.
Looking for retatrutide news or the latest retatrutide research? Here is a plain-language roundup of where the science stands. This is educational research news; retatrutide is Research Use Only and not an approved medicine.
Phase 2: the results that got attention
Retatrutide first drew wide interest when its Phase 2 trial appeared in the New England Journal of Medicine. Eli Lilly reported mean weight reductions of up to 17.5% at 24 weeks and up to 24.2% at 48 weeks in adults with obesity - some of the largest figures reported for this class at the time.
Phase 3 TRIUMPH: the newer data
The Phase 3 program, called TRIUMPH, has since reported strong results. Coverage from AJMC noted up to about 30.3% average weight loss in TRIUMPH-1. A separate trial in adults with obesity and knee osteoarthritis reported 28.7% at the 12 mg level over 68 weeks, along with reported improvements in joint pain.
What is coming next?
Lilly has said several more Phase 3 trials in obesity and type 2 diabetes are expected to complete in 2026. Detailed results are being presented at medical meetings and in journals as they mature. After trials finish, the next milestone would be a regulatory submission.
Why the research community is watching
Retatrutide is the most advanced triple agonist (GLP-1, GIP, and glucagon) in late-stage testing. That is why it appears so often in obesity drug news and why researchers track each readout.
Retatrutide research materials at Dissolv Labs
Dissolv Labs supplies high-purity compounds as reference materials for laboratory research only. They are not for human or animal use.
Frequently asked questions
What is the latest retatrutide news?
Phase 3 TRIUMPH trials have reported large weight reductions, with more readouts expected through 2026.
Is retatrutide approved yet?
No. It remains investigational and is not FDA approved.
Who is developing it?
Eli Lilly and Company, under the TRIUMPH Phase 3 program.
The bottom line
Retatrutide has moved from headline Phase 2 results to strong Phase 3 TRIUMPH readouts, with more data due in 2026. It is still investigational and sold only as Research Use Only material.
Sources
- Eli Lilly: Retatrutide Phase 3 (TRIUMPH) topline results
- AJMC: Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1
- Eli Lilly: Phase 2 retatrutide results published in NEJM
- Drugs.com: Retatrutide history and FDA approval status
Disclaimer: All Dissolv Labs products are sold for Research Use Only and are not for human or veterinary use. This content is educational and is not medical advice, diagnosis, treatment guidance, or a recommendation to consume any substance.
